RGDXQ — Response Genetics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -229.47% | ||
| Return on Equity | n/a | ||
| Operating Margin | -83.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2010 | 2011 | 2012 | 2013 | 2014 | 2015E | 2016E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.28 | 22.64 | 18.74 | 19.8 | 16.72 | n/a | n/a | 13.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
Directors
- Thomas Bologna CHM (71)
- Kevin Harris CFO (48)
- Adanech Getachew GCN (37)
- Kirk Calhoun LED (77)
- Michael Serruya DRC (56)
- Sam Chawla IND (43)
- David Schreiber IND (60)
- Richard van den Broek IND (55)
- David Wurzer IND
- Last Annual
- December 31st, 2014
- Last Interim
- March 31st, 2015
- Incorporated
- September 23rd, 1999
- Public Since
- June 5th, 2007
- No. of Shareholders
- 29
- No. of Employees
- 96
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 38,795,396
- Address
- 1640 Marengo St Fl 7th, LOS ANGELES, 90033-1057
- Web
- Phone
- +1 3232243900
- Auditors
- BDO USA, LLP
Upcoming Events for RGDXQ
Similar to RGDXQ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:18 UTC, shares in Response Genetics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Response Genetics last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Response Genetics share price has underperformed the S&P500 Index by -14.03% over the past year.
There is no consensus recommendation for this security.
Response Genetics does not currently pay a dividend.
Response Genetics does not currently pay a dividend.
Response Genetics does not currently pay a dividend.
To buy shares in Response Genetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Response Genetics had a market capitalisation of .
Here are the trading details for Response Genetics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RGDXQ
Based on an overall assessment of its quality, value and momentum Response Genetics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Response Genetics. Over the past six months, its share price has underperformed the S&P500 Index by -13.32%.
As of the last closing price of $0.00, shares in Response Genetics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Response Genetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Response Genetics' management team is headed by:
- Thomas Bologna - CHM
- Kevin Harris - CFO
- Adanech Getachew - GCN
- Kirk Calhoun - LED
- Michael Serruya - DRC
- Sam Chawla - IND
- David Schreiber - IND
- Richard van den Broek - IND
- David Wurzer - IND